| Detected | Trial | Change |
|---|---|---|
| 2026-08-13 | NCT06139211 A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors |
Trial completed |
| 2026-08-13 | NCT06139211 A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors |
Enrollment reduced: 186 -> 66 participants |
| 2026-08-13 | NCT06139211 A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors |
date change Primary completion pushed: 2025-11-01 -> 2026-05-28 |
| 2026-08-13 | NCT06139211 A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors |
date change Completion pushed: 2026-01-28 -> 2026-05-28 |
| 2026-08-05 | NCT06969027 JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC |
Enrollment closed, study ongoing |
| 2026-08-05 | NCT06969027 JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC |
Enrollment reduced: 84 -> 69 participants |
| 2026-08-05 | NCT06969027 JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC |
date change Primary completion pushed: 2025-11-30 -> 2027-12-31 |
| 2026-08-05 | NCT06969027 JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC |
date change Completion pushed: 2027-12-31 -> 2028-05-31 |
| 2026-07-28 | NCT06095583 Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation… |
Trial sites reduced: 156 -> 76 locations |
| 2026-07-25 | NCT06944470 JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC |
overall status: Not Yet Recruiting → Active, Not Recruiting |
| 2026-07-25 | NCT06944470 JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC |
date change Primary completion pushed: 2026-09-30 -> 2027-04-30 |
| 2026-07-24 | NCT04158440 Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC |
Trial completed |
| 2026-07-24 | NCT04158440 Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC |
date change Primary completion pushed: 2025-06-30 -> 2026-04-18 |
| 2026-07-24 | NCT04158440 Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC |
date change Completion pushed: 2025-12-31 -> 2026-07-03 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05621070 | Efficacy and Safety of JS002 as Monotherapy in Patients With Primary… | Primary Hypercholesterolaemia and Mixed Dyslipidemia | Recruiting |
| NCT06170489 | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected… | Hodgkin Lymphoma | Recruiting |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of… | Intrahepatic Cholangiocarcinoma | Recruiting |
| NCT07284134 | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced… | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT06095583 | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation… | Limited-stage Small Cell Lung Cancer (LS-SCLC) | Recruiting |
| NCT06505837 | JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line… | Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04848753 | Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With… | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Active, Not Recruiting |
| NCT04523493 | Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC | Advanced Hepatocellular Carcinoma (HCC) | Active, Not Recruiting |
| NCT05180734 | PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer | Gastric or Esophagogastric Junction Adenocarcinoma | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical… | Hepatocellular Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06885385 | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in… | Advanced Colorectal Cancer | Recruiting |
| NCT06954467 | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | Recruiting |
| NCT07081022 | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma | B-cell Non-Hodgkin's Lymphoma | Recruiting |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression… | Advanced NSCLC | Recruiting |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | Triple-negative Breast Cancer | Recruiting |
| NCT07484724 | A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With… | Advanced Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT07503756 | JS212 Combination Therapies in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | Recruiting |
| NCT06868836 | Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in… | Non-squamous Non-small Cell Lung Cancer | Recruiting |
| NCT07309276 | A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With… | Advanced Lung Cancer | Recruiting |
| NCT07480733 | Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced… | Advanced Malignant Solid Tumors | Recruiting |
| NCT07518160 | JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study | Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Recruiting |
| NCT06944470 | JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC | NSCLC | Active, Not Recruiting |
| NCT06969027 | JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC | Non-small Cell Lung Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06888830 | A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… | Advanced Malignant Solid Tumours | Recruiting |
| Phase 1 | |||
| NCT06839105 | A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With… | Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor | Recruiting |